[Journal of Drug Targeting] Characterization of an encapsulated insulin secreting human pancreatic b
Type I diabetes mellitus is characterized by the destruction of the insulin producing beta cells within the pancreas by the immune system. After the success of Edmonton protocol, islet transplantation has shown to be a promising therapy, but with the Achilles´ heel of the need of using immunosuppressive drugs. Currently, cell encapsulation technology represents a real alternative to protect transplanted islets from the host´s immune attack. Although preliminary in vitro studies with encapsulated cells have been traditionally performed under static conditions in terms of viability and efficiency, these static cultures do not represent a close approach to in vivo environments. We have developed and characterized different alginate-poly-L-lysine-alginate (APA) microcapsules loaded with the insulin producing 1.1B4 cell line. Static in vitro studies confirmed a constant insulin secretion and a boost of the secretion when the medium was enriched with glucose. Nevertheless, these results were not completely reproduced in a dynamic system by APA liquefied microcapsules containing 1.1B4 cells. The dynamic culture setting created by a microfluidic device, allowed the determination of the glucose response in APA liquefied microcapsules, showing that dynamic conditions can mimic better physiological in vivo environments.
Argia Acarregui, Jesús Ciriza, Laura Saenz del Burgo, Haritz Gurruchaga, José Yeste, Xavier Illa, show all Pages 1-29 | Received 14 Dec 2016, Accepted 18 May 2017, Accepted author version posted online: 23 May 2017 Download citation http://dx.doi.org/10.1080/1061186X.2017.1334208